Health-Related Quality of Life in patients with hepatitis C in double and triple therapy

Detalhes bibliográficos
Autor(a) principal: Fagundes,Raíssa Neves
Data de Publicação: 2015
Outros Autores: Ferreira,Lincoln Eduardo Villela Vieira de Castro, Pace,Fábio Heleno de Lima
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Escola de Enfermagem da USP (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0080-62342015000600937
Resumo: Abstract OBJECTIVE Comparing Health-Related Quality of Life (HRQoL) scores in patients with chronic hepatitis C undergoing double and triple antiviral therapy and analyzing possible factors related to HRQoL. METHOD HRQoL was assessed using the Short Form 36 and Chronic Liver Disease Questionnaire, which were applied at baseline and at weeks 4, 12 and 16 of treatment to 32 patients divided into two groups: double therapy with pegylated interferon (IFN-PEG) and ribavirin, and triple therapy with PEG-IFN, ribavirin and telaprevir. RESULTS The reduction of HRQoL was greater in patients receiving triple therapy compared to those treated with two drugs, the most critical time is at 12 weeks in both groups. After removal of telaprevir, the triple therapy group significantly improved their HRQoL scores. Anxiety and depression before treatment, employment status and race are significantly related to diminished HRQoL. CONCLUSION Patients undergoing double and triple therapy have diminished HRQoL indexes, but the addition of telaprevir chooses a more significant decrease.
id USP-24_49559591df529983400271524c3bd366
oai_identifier_str oai:scielo:S0080-62342015000600937
network_acronym_str USP-24
network_name_str Revista da Escola de Enfermagem da USP (Online)
repository_id_str
spelling Health-Related Quality of Life in patients with hepatitis C in double and triple therapyHepatitis CQuality of LifeCombined Modality TherapyRibavirinInterferonsProtease InhibitorsAbstract OBJECTIVE Comparing Health-Related Quality of Life (HRQoL) scores in patients with chronic hepatitis C undergoing double and triple antiviral therapy and analyzing possible factors related to HRQoL. METHOD HRQoL was assessed using the Short Form 36 and Chronic Liver Disease Questionnaire, which were applied at baseline and at weeks 4, 12 and 16 of treatment to 32 patients divided into two groups: double therapy with pegylated interferon (IFN-PEG) and ribavirin, and triple therapy with PEG-IFN, ribavirin and telaprevir. RESULTS The reduction of HRQoL was greater in patients receiving triple therapy compared to those treated with two drugs, the most critical time is at 12 weeks in both groups. After removal of telaprevir, the triple therapy group significantly improved their HRQoL scores. Anxiety and depression before treatment, employment status and race are significantly related to diminished HRQoL. CONCLUSION Patients undergoing double and triple therapy have diminished HRQoL indexes, but the addition of telaprevir chooses a more significant decrease.Universidade de São Paulo, Escola de Enfermagem2015-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0080-62342015000600937Revista da Escola de Enfermagem da USP v.49 n.6 2015reponame:Revista da Escola de Enfermagem da USP (Online)instname:Universidade de São Paulo (USP)instacron:USP10.1590/S0080-623420150000600009info:eu-repo/semantics/openAccessFagundes,Raíssa NevesFerreira,Lincoln Eduardo Villela Vieira de CastroPace,Fábio Heleno de Limaeng2015-12-08T00:00:00Zoai:scielo:S0080-62342015000600937Revistahttp://www.scielo.br/reeuspPUBhttps://old.scielo.br/oai/scielo-oai.php||nursingscholar@usp.br1980-220X0080-6234opendoar:2015-12-08T00:00Revista da Escola de Enfermagem da USP (Online) - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Health-Related Quality of Life in patients with hepatitis C in double and triple therapy
title Health-Related Quality of Life in patients with hepatitis C in double and triple therapy
spellingShingle Health-Related Quality of Life in patients with hepatitis C in double and triple therapy
Fagundes,Raíssa Neves
Hepatitis C
Quality of Life
Combined Modality Therapy
Ribavirin
Interferons
Protease Inhibitors
title_short Health-Related Quality of Life in patients with hepatitis C in double and triple therapy
title_full Health-Related Quality of Life in patients with hepatitis C in double and triple therapy
title_fullStr Health-Related Quality of Life in patients with hepatitis C in double and triple therapy
title_full_unstemmed Health-Related Quality of Life in patients with hepatitis C in double and triple therapy
title_sort Health-Related Quality of Life in patients with hepatitis C in double and triple therapy
author Fagundes,Raíssa Neves
author_facet Fagundes,Raíssa Neves
Ferreira,Lincoln Eduardo Villela Vieira de Castro
Pace,Fábio Heleno de Lima
author_role author
author2 Ferreira,Lincoln Eduardo Villela Vieira de Castro
Pace,Fábio Heleno de Lima
author2_role author
author
dc.contributor.author.fl_str_mv Fagundes,Raíssa Neves
Ferreira,Lincoln Eduardo Villela Vieira de Castro
Pace,Fábio Heleno de Lima
dc.subject.por.fl_str_mv Hepatitis C
Quality of Life
Combined Modality Therapy
Ribavirin
Interferons
Protease Inhibitors
topic Hepatitis C
Quality of Life
Combined Modality Therapy
Ribavirin
Interferons
Protease Inhibitors
description Abstract OBJECTIVE Comparing Health-Related Quality of Life (HRQoL) scores in patients with chronic hepatitis C undergoing double and triple antiviral therapy and analyzing possible factors related to HRQoL. METHOD HRQoL was assessed using the Short Form 36 and Chronic Liver Disease Questionnaire, which were applied at baseline and at weeks 4, 12 and 16 of treatment to 32 patients divided into two groups: double therapy with pegylated interferon (IFN-PEG) and ribavirin, and triple therapy with PEG-IFN, ribavirin and telaprevir. RESULTS The reduction of HRQoL was greater in patients receiving triple therapy compared to those treated with two drugs, the most critical time is at 12 weeks in both groups. After removal of telaprevir, the triple therapy group significantly improved their HRQoL scores. Anxiety and depression before treatment, employment status and race are significantly related to diminished HRQoL. CONCLUSION Patients undergoing double and triple therapy have diminished HRQoL indexes, but the addition of telaprevir chooses a more significant decrease.
publishDate 2015
dc.date.none.fl_str_mv 2015-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0080-62342015000600937
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0080-62342015000600937
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0080-623420150000600009
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Universidade de São Paulo, Escola de Enfermagem
publisher.none.fl_str_mv Universidade de São Paulo, Escola de Enfermagem
dc.source.none.fl_str_mv Revista da Escola de Enfermagem da USP v.49 n.6 2015
reponame:Revista da Escola de Enfermagem da USP (Online)
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Revista da Escola de Enfermagem da USP (Online)
collection Revista da Escola de Enfermagem da USP (Online)
repository.name.fl_str_mv Revista da Escola de Enfermagem da USP (Online) - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||nursingscholar@usp.br
_version_ 1748936537789169664